AG
VIRX

Algert Global’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Algert Global’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,915
Closed -$23K – 537
2019
Q4 		$23K Hold
1,915
– – 0.01% 369
2019
Q3 		$48K Hold
1,915
– – 0.02% 343
2019
Q2 		$49K Buy
1,915
+1,328
+226% +$51.4K 0.02% 333
2019
Q1 		$25K Buy
+587
New +$13.3K 0.01% 297

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Algert Global's VIRX Position: Q1 2020 in Review

Algert Global sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2020, closing a stake of 1,915 shares — an estimated $23K sold.

Algert Global first reported a position in VIRX in Q1 2019 and held it in 4 quarters. The position peaked at $49K in Q2 2019. 47 funds tracked by Wall St. Rank hold VIRX as of Q1 2020.

  • Algert Global reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Algert Global sold 1,915 Viracta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $23K.
  • Algert Global first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2019 and held it in 4 quarters.
  • Algert Global's Viracta Therapeutics, Inc. Common Stock position peaked at $49K in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Algert Global's 13F filing for Q1 2020, filed 13 May 2020.